Are inhaled longacting β2 agonists detrimental to asthma?
- 1 June 2013
- journal article
- review article
- Published by Elsevier BV in The Lancet Respiratory Medicine
- Vol. 1 (4), 339-346
- https://doi.org/10.1016/s2213-2600(13)70044-4
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Canadian Thoracic Society 2012 Guideline Update: Diagnosis and Management of Asthma in Preschoolers, Children and AdultsCanadian Respiratory Journal, 2012
- Effect of Inhaled Formoterol and Budesonide on Exacerbations of AsthmaNew England Journal of Medicine, 1997
- Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids.American Journal of Respiratory and Critical Care Medicine, 1996
- Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroidThe Lancet, 1994
- Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study.Thorax, 1991
- Formoterol, a new long-acting selective β2-adrenergic receptor agonist: Double-blind comparison with salbutamol and placebo in children with asthmaJournal of Allergy and Clinical Immunology, 1989
- PRESCRIBED FENOTEROL AND DEATH FROM ASTHMA IN NEW ZEALAND, 1981-83; CASE-CONTROL STUDYThe Lancet, 1989
- Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.Thorax, 1988
- RISE AND FALL OF ASTHMA MORTALITY IN ENGLAND AND WALES IN RELATION TO USE OF PRESSURISED AEROSOLSThe Lancet, 1969
- Observations on recent increase in mortality from asthma.BMJ, 1968